NOW AVAILABLE—NEW VECTICAL™ OINTMENT FOR MILD TO MODERATE PLAQUE PSORIASIS



- May be used with other psoriasis agents^{1,2}
- Proven safe and effective in 8-week and 52-week safety studies13
- Convenient BID application³
- No generic equivalent



The most frequent adverse events (≥3%) reported in clinical trials were lab test abnormality, urine abnormality, psoriasis, hypercalciuria, pruritus and skin discomfort. Vectical™ should be used with caution in patients with known or suspected disturbances in calcium homeostasis, who are taking calcium or Vitamin D supplements or who are on diuretics. If aberrations in parameters of calcium metabolism occur, discontinue use until

these normalize. Caution patients to avoid excessive exposure to natural or artificial sunlight after applying the ointment. Avoid contact with eyes, lips and face. Limit use to 200 grams per week.

Please see next page for brief summary of Prescribing Information.

www.Vectical.com

www.Vectical.com

©2009 Galderma Laboratories, L.P. GALDERMA is a registered trademark. Galderma Laboratories, L.P. 14501 N. Freeway, Fort Worth, TX 76177 VEC-317 Printed in USA

References: 1. Data on file. Galderma Laboratories. 2. Lahfa M, Mrowietz U, Koenig M, Simon JC. Calcitriol ointment and clobetasol propionate cream: a new regimen for the treatment of plaque psoriasis. Eur J Dermatol. 2003;13:261-265. 3. Lebwohl M, Menter A, Weiss J, et al. Calcitriol 3 µg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol. 2007;6:428-435. 4. Vectical™ Prescribing Information. Fort Worth, TX: Galderma Laboratories, L.P.; 2009.